多西紫杉醇联合重组人血管内皮抑制素二线治疗晚期非小细胞肺癌

目的：评价多西紫杉醇联合重组人血管内皮抑制素（恩度）二线治疗晚期非小细胞肺癌（ＮＳＣＬＣ）的疗效和毒副反应。方法：采用同期非随机对照方法，共７３例晚期复发的ＮＳＣＬＣ患者入组。２８例患者接受多西紫杉醇联合恩度二线治疗（治疗组），４５例患者接受多西紫杉醇单药二线治疗（对照组），每个周期行影像学检查评价疗效。结果：治疗组和对照组的有效率分别为１７.９％和１３.３％（Ｐ＝０.８５０），疾病控制率分别为６４.３％和５３.３％（Ｐ＝０.３５７），中位无进展生存期（ＰＦＳ）分别为４个月和３个月（Ｐ＝０.０１５），中位生存期（ＯＳ）分别为８个月和６个月（Ｐ＝０.０３０）。两组常见的毒副反应是骨髓抑制、脱发、乏力、关节酸痛，治疗组和对照组的差异无统计学意义（Ｐ＞０.０５）。结论：多西紫杉醇联合重组人血管内皮抑制素二线治疗既往化疗失败的晚期ＮＳＣＬＣ，能够提高患者ＰＦＳ和ＯＳ，且毒副反应无明显增加。

Docetaxel plus rh-endostatin in second-line therapy of advanced non-small cell lung cancer

Objective:To evaluate the toxicity and efficacy of docetaxel plus rh-endostatin (endostar) as the second-line therapy of advanced non-small cell lung cancer(NSCLC). Methods:Seventy-three recurrently advanced NSCLC patients were enrolled. Twenty-eight patients were divided into group therapied by docetaxel plus endostar(experimental group). And 45 patients were divied into group therapied only by docetaxel(control group). Efficacy were estimated by imaging every cycle. Results:The efficacies of experimental group and control group were 17.9% and 13.3%(P=0.850). The disease control rates were 64.3% and 53.3%(P=0.357). The median progression-free survival(PFS)were 4 months and 3 months(P=0.015). The median overall survival(OS)were 8 months and 6 months(P=0.030). The most common toxicity were myelosuppression, alopecia, asthenia, joint pain. The differences of experimental group and control group were not statisticaliy significant(P＞0.05). Conclusion:PFS and OS were possibly extended by docetaxel plus endostar as second-line therapy in the advanced relaped NSCLC patients. But the toxicity were not significantly increased.